HIF1α inhibition by dual targeting of CDK4/6 and HSP90 reduces cancer cell viability including Rb-deficient cells

Shuai Zhao¹⁻⁴, Lanlan Zhou¹,³⁻⁵, David T. Dicker¹,³,⁴, Avital Lev⁶, Shengliang Zhang¹,³⁻⁵ and Wafik S. El-Deiry¹⁻⁷,*

¹Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI, USA.

²Pathobiology Graduate Program, Brown University, Providence, RI, USA.

³Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.

⁴Joint Program in Cancer Biology, Brown University and Lifespan Cancer Institute, Providence, RI, USA.

⁵Cancer Center at Brown University, Warren Alpert Medical School, Brown University, Providence, RI, USA.

⁶Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.

⁷Hematology/Oncology Division, Lifespan Cancer Institute, Providence, RI, USA

*Corresponding author: wafik@brown.edu

Key Words: CDK4/6; HSP90; HIF1alpha; hypoxia; cancer therapy, Rb

Running Title: CDK4/HSP90 inhibition of HIF1alpha as cancer therapy
Abstract

Most cancers harbor intra-tumoral hypoxia which promotes tumor progression and therapy resistance. Hypoxia-inducible factor 1α (HIF1α) mediates an adaptive response to hypoxia and contributes to multiple cancer hallmarks. We describe cancer therapeutic targeting of HIF1α by combination of CDK4/6 inhibitors (CDK4/6i) and heat-shock protein 90 inhibitors (HSP90i). CDK1 contributes to HSP90-mediated HIF1α stabilization whereas CDK1-knockdown enhances HIF1α reduction by HSP90i. Dual CDK1- and HSP90-inhibition increases apoptosis and synergistically inhibits cancer cell viability. To translate our findings, we use FDA-approved CDK4/6i in combination with HSP90i to reduce HIF1α expression and suppress viability of multiple cancer cell types, including Rb-deficient cancer cells. Overexpression of HIF1α668E partially rescues the cell viability inhibition by combination CDK4/6i and HSP90i treatment under hypoxia. CDK4/6i and HSP90i suppresses tumor growth in vivo. Thus, combined targeting of CDK4/6 and HSP90, through a drug class effect, inhibits HIF1α and shows preclinical anti-cancer therapeutic efficacy, including with Rb-deficiency.
Introduction

Accompanying the unrestrained proliferation of malignant cells, solid tumors are generally deprived of an adequate oxygen supply\(^1\). Regions located further than the oxygen diffusion limit (~100 µm)\(^2\) to blood vessels become hypoxic. Hypoxia is implicated in cancer, linked to abnormal vascularization, altered metabolism, resistance to chemo-/radio-therapy, as well as increased cancer cell stemness and metastasis\(^3\)\(^-\)\(^7\). In adaptation to hypoxia, hypoxia-inducible factor 1 (HIF1), as a transcription factor, stimulates a variety of target genes that are involved in altered metabolism, cell survival and tumor progression\(^8\)\(^-\)\(^10\). In particular, the α subunit of HIF1, HIF1\(\alpha\), becomes constitutively expressed, which leads to the constant activation of HIF1.

Overexpression of HIF1\(\alpha\) is observed in a variety of cancers. In colorectal cancer (CRC), it is associated with poor prognosis and early progression\(^11\)\(^,\)\(^12\). HIF1\(\alpha\) inhibits apoptosis\(^13\)\(^,\)\(^14\), facilitates cell migration\(^14\) and promotes angiogenesis through upregulation of the target \(VEGF\) gene\(^15\) in CRCs and other tumors. When oxygen is sufficient, in normal cells, HIF1\(\alpha\) is hydroxylated by prolyl hydroxylase-domain proteins (PHDs) and is targeted by the von Hippel-Lindau (VHL) protein complex for ubiquitination and subsequent proteasomal degradation\(^16\), which is prevented by hypoxia\(^17\). However, elevated HIF1\(\alpha\) expression is not exclusive to hypoxic conditions. In renal cell carcinomas, VHL is frequently mutated and deficient\(^18\). In RCC4 renal cancer cells, for instance, HIF1\(\alpha\) is constantly expressed at increased levels due to protein stabilization. EGF/EGFR signaling transcriptionally activates HIF-1\(\alpha\) independently of hypoxia\(^19\). Moreover, HIF1\(\alpha\) was shown to be detectable at other regions in the tumor other than the hypoxic necrotic margin\(^20\). HIF1\(\alpha\) can accumulate in T\(_H\)17 cells under normoxia and regulates T\(_H\)17 differentiation, suggesting a role of HIF1\(\alpha\) in the immune system in both normoxia and hypoxia\(^21\).

We previously carried out a chemical library screen for hypoxia sensitizers and uncovered cyclin-dependent kinase inhibition as a potential therapeutic strategy for hypoxic tumors\(^22\). We further showed that cyclin-dependent kinase 1 (CDK1) stabilizes HIF1\(\alpha\) through phosphorylation of the Ser668 residue of HIF1\(\alpha\) protein\(^23\). Such stabilization occurs not only in hypoxia, but also at the G2/M cell cycle phase under normoxic conditions. Moreover, CDK4 is also important for HIF1\(\alpha\) stabilization, as we uncovered in our study through knockdown of CDK proteins\(^23\).
RCC4 cells demonstrated that the CDK1- or CDK4- inhibitor-mediated HIF1α destabilization is independent of a functional VHL protein.

Another VHL-independent HIF1α stabilizer is the heat shock protein 90 (HSP90)\(^{24}\). HSP90 is a HIF1α-associated protein\(^{25}\). Overexpression of HSP90 has been correlated with adverse prognosis and recognized as a therapeutic target in cancer (e.g. esophageal squamous cell carcinoma, melanoma, leukemia)\(^{26-28}\). Both CDK and HSP90 inhibitors have been widely studied\(^{29,30}\). Ro-3306 is a CDK1-selective inhibitor\(^{31}\). The CDK4/6 inhibitor, palbociclib, among others has been approved by the FDA in combination treatment for breast cancer\(^{32,33}\). HSP90 inhibitors have evolved from the classical small molecule geldanamycin to second generation compounds (e.g. ganetespib\(^{34}\)). In colorectal cancer, ganetespib has been found to inhibit angiogenesis\(^{35}\) and sensitizes cells to radiation and chemotherapy\(^{36}\).

We initially investigated the hypothesis that CDK1 and HSP90 signaling overlaps in the regulation of HIF1α, and that combination treatment to target both CDK1 and HSP90 may lead to enhanced inhibitory effects towards HIF1α expression and function as well as improved anti-cancer efficacy. We extended our observations to CDK4/6 inhibitors given the fact there are several FDA-approved drugs allowing more rapid translation of our findings. We uncovered a synergy between CDK4/6 inhibitors and HSP90 inhibitors, as a class effect for each of the two drug classes, through convergence upon HIF1α leading to cell death. Importantly, the dual blockade of CDK4/6 and HSP90 is observed in Rb-deficient tumor cells suggesting a novel approach for cancer therapy. We investigated overexpression of HIF1α\(^{668E}\), a mimic of phosphorylated HIF1α, and showed that it partially rescues cell viability inhibition by combined CDK4/6i and HSP90i treatment under hypoxia. An additional aspect of this work involves a focus on HIF as a potential biomarker for CDK4/6-HSP90 dual inhibition therapy. Overall, our results suggest a novel therapy combination that is efficacious in preclinical models for targeting hypoxic tumor cells and this could be further advanced and tested in clinical trials.
Results

CDK1 contributes to HSP90-mediated HIF1α stabilization

We have previously reported that knockdown of CDK1 led to the reduction of HIF1α level in RCC4 VHL-deficient cells\textsuperscript{23}. To reinforce the hypothesis that the regulatory effect on HIF1α by CDK1 inhibition is independent of VHL, we examined the level of HIF1α upon addition of CDK1 inhibitor, Ro-3306, in both RCC4 and RCC4\textsuperscript{VHL+} cells. As expected, HIF1α was constantly expressed in RCC4 cells under normoxia, owing to the loss-of-function mutation of \textit{VHL} in this cell line. In accordance with previous results, CDK1 inhibition reduced HIF1α level in RCC4 in normoxia, which could be reversed by proteasome inhibition with MG132 (Fig. 1A). In RCC4\textsuperscript{VHL+} cells where VHL is stably reintroduced, HIF1α expression was dramatically decreased in normoxia compared to that in RCC4 cells. Inhibition of CDK1 decreased the level of HIF1α in RCC4\textsuperscript{VHL+} cells, which could be rescued with MG132 (Fig. 1A). Thus, CDK1 inhibition destabilized HIF1α in a VHL-independent manner.

Another previously known VHL-independent HIF1α stabilizer and associating partner is HSP90\textsuperscript{ref24,25}. We asked whether there is a link between CDK1-mediated and HSP90-mediated stabilization of HIF1α. We found that inhibition of CDK1 impaired the interaction between HIF1α and HSP90 (Fig. 1B). Moreover, heat shock (40°C) induced HIF1α expression in normoxia, which could be partially reversed by treatment with HSP90 inhibitor, geldanamycin, or CDK1 inhibitor, Ro-3306 (Fig. 1C). These results suggest that CDK1 may contribute to the stabilization of HIF1α by HSP90.

Dual targeting of CDK1 and HSP90 robustly reduces the expression level of HIF1α

On basis of the findings above, we tested whether targeting CDK1 could enhance the inhibitory effect on HIF1α expression by HSP90 inhibitors. Consistent with previous findings, the level of hypoxia-induced HIF1α was decreased by CDK1 knockdown or HSP90 inhibition with geldanamycin. Remarkably, when geldanamycin was added to CDK1-knockdown cells, the reduction of HIF1α was further enhanced (Fig. 2A). Such enhanced HIF1α inhibition was also
observed with combination treatment using the two inhibitors, Ro-3306 and geldanamycin (Fig. 2B).

It is known that p53 is mutated in approximately 40%-50% of sporadic colorectal cancers, we tested whether the absence of p53 affects the combinational effect. In HCT116 p53<sup>-/-</sup> cells, combination treatment robustly diminished the level of HIF1α similarly as in wild-type cells (Fig. 2C), indicating that the HIF1α-regulatory effect is p53-independent. Consistently with these observations, the enhanced inhibition of HIF1α by combination treatment was observed in other colorectal cancer cells with different p53 status (Fig. 2D) (i.e. HT29: p53<sup>G273A</sup>; DLD1: p53<sup>C241T</sup>, SW480: p53<sup>G273A&C309T</sup>; RKO: p53<sup>wild-type</sup>).

**Dual inhibition of CDK1 and HSP90 synergistically suppresses cancer cell viability**

The universal effect of HIF1α inhibition by combination of CDK1 knockdown and HSP90 inhibition among various colorectal cancer cell lines prompted us to investigate the therapeutic potential of such combination strategy. We performed a CellTiter-Glo assay to assess the combinatorial effect on cell viability by CDK1 and HSP90 inhibitors. We found that Ro-3306 and geldanamycin synergistically inhibited HCT116 cell viability in both normoxia and hypoxia (Fig. 3A, B).

Subsequently we asked whether apoptosis was induced by the combination treatment. We performed sub-G1 analysis by flow cytometry to estimate fractional DNA content. Combination of Ro-3306 and geldanamycin significantly increased the sub-G1 population in HCT116 cells as compared to control and single treatments in either normoxia or hypoxia (Fig. 3C), indicating the increased occurrence of apoptosis. As expected, PARP cleavage was also observed (Fig. 3D) at an earlier time point as a marker of initiated apoptosis. In addition, the robust synergy on cell viability inhibition was abrogated in HCT116 Bax<sup>-/-</sup> cells (Fig. 3E), indicating that Bax may play an important role in mediating cell death induced by the CDK1i/HSP90i combination treatment.

**Dual inhibition of CDK1 and HSP90 represses the ability of colony formation and cell migration**
Not every single cancer cell is capable of proliferating into a colony\textsuperscript{40}. To determine whether the combination treatment as well induces cell reproductive death in an \textit{in vitro} model, we performed clonogenic assays to test the post-treatment change in cell capability to generate colonies. Treatment with both Ro-3306 and geldanamycin, at relatively low doses (2.5 µM, 0.02 µM, respectively), markedly inhibited colony formation of HCT116 cells in both normoxia (Fig 4A) and hypoxia (Fig. 4B). The colonies that formed upon combination treatment were fewer in number and smaller in size as compared to control and single treatments. Thus, the dual inhibition of CDK1 and HSP90 inhibits colony formation by HCT116 colon cancer cells.

The overexpression of HIF1\(\alpha\) in cancer is implicated not only in promoting cell survival but also in cell migration\textsuperscript{41}. We performed an \textit{in vitro} scratch assay\textsuperscript{42} to test the effect of combination treatment on HCT116 motility. An artificial gap was created on a nearly confluent monolayer of cells. The cell monolayer bearing wounds was treated with single or combination of the two inhibitors, together with Z-VAD-FMK, a pan-caspase inhibitor to prevent treatment-induced cell death. Gap ratio was calculated using gap width at 48 hours normalized to that at 0 hour. The ratio was significantly higher in the combination treatment group as compared to the control and single treatment groups (Fig. 4C, D), suggesting that the combination of Ro-3306 and geldanamycin inhibits HCT116 cell migration.

\textbf{Dual inhibition of CDK4/6 and HSP90 shows anti-cancer effects}

We have previously shown that knockdown of CDK4 was able to reduce the level of HIF1\(\alpha\)\textsuperscript{23}. Considering the clinical use of the FDA-approved CDK4 inhibitors, we sought to examine the anti-cancer effects by CDK4 inhibition in combination with HSP90 inhibitors. Two different HSP90 inhibitors, ganetespib and onalespib, were tested first in the study. As expected, either ganetespib or onalespib alone reduced the expression level of HIF1\(\alpha\) (Fig. 5A, B). The addition of CDK4 inhibitor, palbociclib, was able to further enhance the HIF1\(\alpha\) decrease induced by HSP90 inhibition (Fig. 5A, B). Knockdown of CDK4 with siRNA exhibited a similar effect (Supplementary Fig. 1A). Combination treatment with palbociclib and either of the HSP90 inhibitors showed synergistic inhibition on cell viability in HCT116 cells in both normoxia and
hypoxia (Fig. 5C, D). Such synergy was also observed in other colorectal cancer cells (e.g. SW480, Supplementary Fig. 1B, C). Dual inhibition of CDK4 and HSP90 significantly increased the sub-G1 population in HCT116 cells regardless of oxygen concentration (Fig. 5E). Combination treatment with palbociclib and ganetespib significantly inhibited HT29 cell migration in CoCl2-treated cells where hypoxia is mimicked (Fig. 5F). These results indicate that targeting CDK4/6 in combination with HSP90 inhibition has a similar anti-cancer effect as dual inhibition of CDK1 and HSP90.

CDK4/6 inhibitors have been intensively studied in combination therapies. After palbociclib, two CDK4/6 inhibitors, ribociclib and abemaciclib, were approved as anti-cancer drugs. Meanwhile there have been many efforts in developing HSP90 inhibitors intended for cancer treatment with tolerable toxicity. To further test the translational potential of the dual inhibition strategy, we included the CDK4/6 inhibitor abemaciclib and two other HSP90 inhibitors that were being examined in clinical trials, XL-888 and TAS-116, in this study. Consistent with the results above, XL-888, in combination with palbociclib, exhibited similar inhibitory effects on HIF1α expression as well as cell viability (Supplementary Fig. 2). The combination of TAS-116 and palbociclib or abemaciclib markedly reduced the level of HIF1α (Supplementary Fig. 3A, D) and synergistically suppressed cell viability in SW480 colon cancer cells both in normoxia (Supplementary Fig. 3B, E) and hypoxia (Supplementary Fig. 3C, F).

These results not only established the preclinical foundation for potentially testing these drugs in clinical trials, but further confirmed a class effect of CDK4/6 and HSP90 dual inhibition in colorectal cancer treatment.

**Anti-tumor efficacy in vivo by combination treatment with palbociclib and ganetespib**

To determine the anti-tumor efficacy of CDK4/6 and HSP90 dual inhibition in vivo, we used HT29 cancer cells in a xenograft mouse model. HT29 is relatively resistant to ganetespib compared to other colorectal cancer cell lines (Supplementary fig. 4). We tested whether the addition of palbociclib could improve the tumor-suppressive performance of ganetespib. The weight of drug combination-treated tumors was significantly lower than that of control and single treatment
groups (Fig. 6A, B). Relative tumor volume was also low in the combination treatment group (Fig. 6C). There was no evident toxicity or weight loss observed upon the combination treatment compared to the control group (Fig. 6D), indicating the safety of simultaneous administration with palbociclib and ganetespib.

Interestingly, the combination treatment reduced the presence of microvessels in tumors (Fig. 6E), which is consistent with suppression of the role of HIF1α in angiogenesis. In addition, the combination treatment increased caspase 3 cleavage and inhibited VEGF expression in the xenografts (Supplementary fig. 5). The in vivo results suggest a therapeutic potential of the CDK4/6 and HSP90 dual inhibition strategy in cancer treatment.

**Combination treatment of CDK4/6 and HSP90 inhibitors synergistically inhibit cell viability in multiple cancer types**

Although the dual inhibition was mainly evaluated in colorectal cancers in this study, the strategy is not necessarily limited to one cancer type. CDK4/6 inhibition was initially investigated and approved for treatment in breast cancers. Hypoxia is a prominent characteristic of the tumor microenvironment in pancreatic cancer and glioblastoma, both of which lack efficacious treatments. Thus, we tested the effect of CDK4/6 and HSP90 dual targeting on HIF1α expression in various cancer cell lines. In our later studies, we have focused on using TAS-116 as the HSP90 inhibitor as it is currently being tested in early phase clinical trials for cancer. Enhanced HIF1α inhibition was shown upon the combination treatment of palbociclib and TAS-116 in ASPC1 and HPAFII pancreatic cancer cell lines (Supplementary fig. 6A, B) as well as SKBR3 and MDA-MB-361 breast cancer cells (Supplementary fig. 6C, D). Palbociclib and TAS-116 synergistically inhibited SKBR3 cell viability in both normoxia and hypoxia (Supplementary fig. 6E, F). Moreover, ganetespib and palbociclib diminished HIF1α expression in T98G glioblastoma cells (Supplementary fig. 7A). We have also found that knockdown of CDK4 in combination with HSP90 inhibition inhibited the level of HIF1α in PC3 prostate cancer cell line (Supplementary fig. 7B). These findings suggest that it may be worthwhile to pursue the translational potential of such combination treatment in more cancer types. We are currently pursuing a novel phase 1b clinical trial combining palbociclib with TAS116 in patients with breast cancer and other solid tumors.
Rb-deficiency does not block the combinatorial inhibition of HIF1α and reduced cancer cell viability due to targeting of CDK4/6 and HSP90

Rb is a key downstream factor of CDK4/6 activity in cell cycle regulation. Loss of Rb protein is believed to convey resistance to CDK4/6 inhibitors. Here we tested whether the inhibitory effect by the combination treatment was diminished by Rb-deficiency. Saos2 is an osteosarcoma cell line which is naturally Rb-deficient. The combination treatment with abemaciclib and TAS116 synergistically inhibited cell viability at different doses in Saos2 cells in normoxia and hypoxia (Fig. 7A, B). We also knocked down Rb in Rb-proficient (wild-type) cell lines. Knockdown of Rb in SW480 cells and MCF7 cells did not affect the inhibitory effect on HIF1α expression upon combination treatment (Fig. 7C, D). The combination treatment also showed synergistic inhibition of cell viability in Rb-knockdown SW480 cells (Fig. 7E, F).

HIF1α targets VEGFA and SLC2A1 correlate with poor disease-free prognosis in colorectal cancer

HIF1α is involved in multiple key signaling pathways in cancer progression. We analyzed the TCGA database on colon and rectal cancer using UCSC Xena online exploration tool. The overexpression of HIF1α target genes VEGFA and SLC2A1 correlated with poor disease-free prognosis in colorectal cancer (Fig. 8). In clinic, pancreatic cancer is often highly hypoxic. The overexpression of HIF1α target genes SLC2A1 and PPIA are associated with poor prognosis in pancreatic adenocarcinoma (Supplementary fig. 12A). Thus, targeting HIF1α may serve as a promising modality in cancer treatment as the poor prognostic factors would be inhibited by the proposed dual CDK4/6 and HSP90 inhibition strategy. Both HIF1α and its targets could serve as useful biomarkers in future clinical trials of dual CDK4/6 and HSP90 inhibitor therapy.
Discussion

We demonstrate a novel convergence of CDK4/6 and HSP90 dual inhibition on HIF1\(\alpha\) inhibition that is VHL-, p53-, or hypoxia-independent and which can be translated as a cancer therapy, including for tumors with Rb-deficiency. In this regard, the data in this manuscript provides the preclinical rationale for a planned clinical trial combining CDK4/6 inhibitor palbociclib with HSP90 inhibitor TAS-116. The trial is planned for patients with breast cancer who have progressed on CDK4/6 inhibitor therapy and for patients with other solid tumors that are Rb-deficient. The patent by Zhao S. and El-Deiry W.S., “Dual Inhibition of CDK and HSP90 Destabilizes HIF1\(\alpha\) and Synergistically Induces Cancer Cell Death”, US Patent 10,729,692 issued on August 4, 2020.

Hypoxia and HIF1\(\alpha\) contribute to the malignant cancer progression phenotype across diverse cancer types. HIF1\(\alpha\) is hyperactivated and participates in promoting breast cancer progression\(^{43,44}\). Anabolic metabolism induced by HIF1\(\alpha\) leads to gemcitabine resistance in pancreatic cancer\(^{45}\). Also, hypoxia/HIF1\(\alpha\) exerts a tumor-promoting role by immunosuppression. HIF-1\(\alpha\)/VEGF-A signaling is indispensable for the tumor infiltration and cytotoxicity of effector CD8\(^+\) T cells in breast cancer\(^{46}\). Depletion of HIF1\(\alpha\) in natural killer (NK) cells disturbs angiogenesis and inhibits tumor growth in the MC38 (colon cancer) isograft mouse model\(^{47}\). The immune checkpoint protein PD-L1 has been identified as a direct target of HIF-1\(\alpha\)\(^{48}\). Meanwhile the pro-cancer effect by hypoxia is not limited to solid tumors. Indeed, the local oxygen tension appears quite low in bone marrow \textit{in vivo}\(^{49}\). Hypoxia/HIF1\(\alpha\) signaling maintains leukemia stem cells\(^{50}\) and facilitates invasion and chemo-resistance\(^{51}\) in T-ALL. It may be useful in cancer therapy to pursue effective strategies of targeting hypoxia and HIF1\(\alpha\) signaling.

On the basis of our previous findings showing CDK1-mediated stabilization of HIF1\(\alpha\) and also with the established role of HSP90 in HIF1\(\alpha\) expression, we hypothesized a model where CDK1 contributes to HSP90-mediated stabilization of HIF1\(\alpha\). In our present studies, dual targeting of CDK1 or CDK4/6 and HSP90 robustly reduced the level of HIF1\(\alpha\) and synergistically inhibited cell viability in colorectal cancer lines. To assess the anti-tumor effect, the combination of palbociclib and ganetespib was tested on HT29 xenografts. Palbociclib has been used in a colon carcinoma xenograft model at the dose up to 150 mg/kg p.o. once per day to achieve tumor burden.
suppression\textsuperscript{52}. Ganetespib has been used in a HCT116 xenograft colon cancer model at 150 mg/kg i.v. once per week to inhibit tumor growth\textsuperscript{36}. In the present study, we administrated into the mice considerably lower doses of both compounds (palbociclib at 50 mg/kg; ganetespib at 25 mg/kg). We expect for therapeutic purposes, there would be less toxicity associated with HSP90 inhibition by reduced dosing in this strategy. As the result showed, body weights were not affected by the combination therapy compared to control. However, this does not necessarily preclude the possibility of increasing the doses of each drug in case they are well-tolerated. In the relative tumor volume measurement (Fig. 6C), although an inhibitory trend was shown by combination treatment, no significant difference was indicated by statistical analysis between the palbociclib alone and the combination groups. This may be due to the accuracy of measurements, variation among individual subjects and limited numbers of animals per group. Notably, HT29 is a relatively resistant cell line to ganetespib. The combination with palbociclib sensitized the xenografts for ganetespib treatment. Combination of palbociclib and ganetespib did not trigger synergistic toxicity to WI38 normal cells in normoxia \textit{in vitro} (Supplementary fig. 8). Recently, efforts have been made to develop new generation of HSP90 inhibitors, which may contribute alternative choices other than ganetespib itself. Thus, we are planning to use HSP90 inhibitor TAS-116 in combination with palbociclib in a planned clinical study based on the rationale provided in this manuscript.

Due to the involvement of HIF1\(\alpha\) in multiple aspects in cancer biology, whether the combination treatment affects other HIF1\(\alpha\)-mediated cancer phenotypes remains to be tested. For instance, HIF1\(\alpha\) plays an essential role in stem cell-induced target cell invasion\textsuperscript{53}. Hypoxia/HIF1\(\alpha\) can regulate cancer stem cell-like features\textsuperscript{54,55}. It is not clear whether the CDKi (CDK inhibition) plus HSP90i (HSP90 inhibition) treatment modulates cancer stemness. Also, the effect of combination treatment on metastasis remains to be unraveled, considering the function of HIF1\(\alpha\) as a driving force for metastasis/invasiveness\textsuperscript{14,56-58}. In addition, since hypoxia/HIF1\(\alpha\) is implicated in many immunosuppressive mechanisms\textsuperscript{59-62}, it will be of interest to determine whether the combination CDKi/HSP90i treatment modulates the immune response for anti-tumor activities. CDK inhibition has recently been shown to stimulate tumor immune response\textsuperscript{53-65}. Furthermore, it remains undefined whether any predictive biomarker(s) could be used to indicate sensitivity to the combination CDKi/HSP90i treatment. In this regard, HIF expression and HIF targets are prime
candidate biomarkers. The enhanced inhibition of HIF1α by combined targeting of CDK1 or CDK4/6 and HSP90 was observed in multiple tumor cell lines. It would be useful to explore the anti-cancer effect of combination CDKi/HSP90i treatment in additional cancer types, and based on our results, we plan to include Rb-deficient solid tumors in the phase 1b study.

We performed a preliminary test on HIF2α expression. The combination treatment slightly reduced the level of HIF2α in HCT116 cells at 6 hours (Supplementary fig. 9). It may be interesting to investigate the effect on HIF2α according to its role in different cancer types (e.g. clear-cell renal cell carcinoma).

To test the involvement of HIF1α in the combination treatment, we transiently transfected HCT116 cells with plasmids containing HA alone or HA-HIF1α<sup>668E</sup>, a HIF1α mutant that remains stable upon CDK inhibition. Overexpression of HIF1α<sup>668E</sup> partially rescued the cell viability inhibition by combination treatment under hypoxia (Supplementary fig. 10), indicating that HIF1α may play a role in the combination effect. Since E2F signaling serves as an indicator of CDK4/6 activity, we performed a Pearson correlation test on some of the HIF1α and E2F target genes using the GEPIA tool based on TCGA colon adenocarcinoma data and pancreatic adenocarcinoma data, and found correlations between the expression of several HIF1α and E2F targets (Supplementary fig. 11 & Supplementary fig. 12B), which is consistent with the concept that CDK4/6 activity is linked to HIF1α signaling in patient tumors. As both Rb and HIF1α are molecular substrates for CDK4/6, we would suggest that HIF1α is a relevant and important target for CDK4/6 inhibitor therapy. In that context, HIF1α and its transcriptional targets may serve as useful biomarkers for drug efficacy, and the blockade of HIF1α may contribute to the anti-tumor effects of CDK4/6 inhibitors.

In summary, we provide a rationale for targeting HIF1α through a novel combination of CDK and HSP90 inhibitors as a potential therapeutic strategy. Our findings suggest new applications of previously approved CDK4/6 inhibitory drugs and novel HSP90 inhibitory agents in combination therapies in multiple cancer types including Rb-deficient tumors.
Materials and Methods

Cell culture

HCT116, SW480, HT29, DLD1 and RKO cells were obtained from American Type Culture Collection. HCT116, HT29 and SKBR3 cells were maintained in McCoy’s 5A medium (Hyclone) with 10% fetal bovine serum (FBS, Hyclone) and 1% penicillin/streptomycin (P/S). SW480, DLD1, RCC4, ASPC1, HPAFII, and T98G cells were maintained in Dulbecco’s modified Eagle medium (Hyclone) with 10% FBS and 1% P/S. RKO cells and PC3 cells were maintained in RPMI 1640 medium (Hyclone) with 10% FBS and 1% P/S. MDA-MB-361 cells were maintained in DMEM-F12 with 10% FBS, 1% P/S and 1% glutamine. Saos2 cells were maintained in McCoy’s 5A medium with 15% FBS and 1% P/S. WI-38 cells were maintained in Eagle's Minimum Essential Medium with 10% FBS and 1% P/S. Cells were regularly tested for mycoplasma and authenticated. All cell lines were maintained at 37°C in 5% CO₂. As for hypoxia treatment, cells were kept in a hypoxia chamber (In vivo2, Ruskinn) which maintains 0.5% O₂.

Antibodies and reagents

HIF1α and Ran antibodies were purchased from BD Biosciences. CDK1 and CDK4 antibodies were purchased from Santa Cruz Biotechnology. HA, Rb, HSP90, PARP and cleaved PARP antibodies were purchased from Cell Signaling Technology. Actin antibody was purchased from Sigma. HIF2α antibody was purchased from Novus Biologicals. MG-132 was purchased from Sigma. Ro-3306 was purchased from Santa Cruz Biotechnology. PD-0332991 (palbociclib) was purchased from Medkoo Biosciences. Geldanamycin was purchased from Invivogen. Ganetespib was purchased from ApexBio or Medkoo Biosciences. Onalespib was purchased from Cayman Chemical Company. XL888 was purchased from Medkoo Biosciences. TAS-116 was purchased from Active Biochem.

Western blot
Treated cells were lysed in RIPA buffer (Sigma). Protein concentrations were determined using a BCA Protein Assay Kit (Life Technologies). Equal amounts of total protein were boiled with NuPAGE™ LDS sample buffer (Thermo Fisher Scientific) and reducing agent (Invitrogen) or 2-Mercaptoethanol. Samples were analyzed with SDS-PAGE. Proteins were transferred to an Immobilon-P PVDF membrane (EMD Millipore). Primary and secondary antibodies were added in order. Signals were detected after addition of the ECL western blotting substrate (Thermo Fisher Scientific).

**Cell transfection**

Transient transfection of DNA was performed using Opti-MEM (Thermo Fisher Scientific) and Lipofectamine 2000 (Life Technologies). pcDNA3-HA-HIF1α plasmid was a gift from William Kaelin (Addgene plasmid #18949) 66. Knockdown experiments were performed with Opti-MEM and Lipofectamine RNAiMAX (Life Technologies), according to the manufacturer’s protocol. Control, CDK1 and CDK4 siRNAs were purchased from Santa Cruz Biotechnology. Rb siRNA was purchased from Cell Signaling Technology.

**Immunoprecipitation**

HCT116 cells were transiently transfected with pcDNA3-HA-HIF1α. After 24 hours, cells were treated in hypoxia for 6 hours with MG132 (1 µM). Cells were washed with PBS and fixed in 4% formaldehde. Cell lysis was performed in RIPA buffer with gentle sonication. The protein concentration in the lysates was measured and equalized. Part of the lysate was analyzed by SDS-PAGE and western blot for input monitoring. The remaining majority of the lysate was incubated with anti-HA antibody overnight at 4°C, followed by precipitation with Protein A/G Ultra link Resin (Thermo Fisher Scientific) for 2-4 hours.

**Synergy analysis**

Indicated cells were seeded in a 96-well black microplate (Greiner Bio-One) and treated with combinations of inhibitors at various concentrations for 48 or 72 hours in normoxia or hypoxia.
CellTiter-Glo reagent (Promega) was added and mixed on an orbital shaker at room temperature. Luminescence was recorded as a readout to compare viable cell number difference. Combination index between two treatments was calculated using Compusyn software. Synergism was indicated by a combination index value of $< 1$.

**Colony formation assay**

Cells were seeded at the concentration of 500 cells/well in a 6-well plate and allowed to attach overnight. After subsequent drug treatment for 72 hours, the culture media was substituted with fresh drug-free complete media. Cells were kept in culture for one to two weeks with medium replacement every three days. At the endpoint, cells were rinsed with PBS and fixed with 10% formalin for 15 min. 0.05% crystal violet was used to stain the colonies. Plates were rinsed carefully in the sink with tap water and let dry at room temperature.

**Sub-G1 analysis**

HCT116 cells were treated with indicated reagents for 48 or 72 hours in normoxia or hypoxia. Culture media including floating cells were collected and combined with trypsinized (Gemini Bio-Products) attached cells. All harvested cells were washed in PBS with 1% FBS. Cells were fixed with cold 70% ethanol at 4 °C. Subsequently, cells were washed, incubated in phosphate citrate buffer, and stained with propidium iodide (Sigma). The percentage of cells with sub-G1 DNA content was analyzed by propidium iodide staining and flow cytometry.

**Wound healing assay**

The indicated cell lines were plated in 12-well plates at 80–90% confluence. Scratch lines were made with a 200-µL pipette tip. After washing with PBS, cells were cultured in media containing reagents as indicated. Images were captured at both the beginning and end of the experiment. Gap width was measured in each image. Each treatment group contained three replicates.

**In vivo studies**
Animal experiments were conducted in compliance with the Institutional Animal Care and Use Committee at Fox Chase Cancer Center and followed the Guide for the Care and Use of Laboratory Animals. Hairless combined immunodeficient (SCID) mice were monitored in the Laboratory Animal Facility at Fox Chase Cancer Center. HT29 cells were subcutaneously injected into both rear flanks of 4-week old mice at 1×10^6 / 100 µL in Matrigel/PBS. Treatments were started when tumors reached 100-125 mm³ as measured by Vernier caliper. Tumor-bearing mice were treated with palbociclib or ganetespib or the combination of both. Palbociclib was administered orally via gavage at 50 mg/kg daily (dissolved in ddH2O). Ganetespib was administered intravenously via retro-orbital injection at 25 mg/kg weekly (dissolved in 10% DMSO, 18% Cremophor RH 40, 3.8% dextrose). Growth of tumors was monitored for three weeks. At the endpoint, mice were euthanized, and tumors were dissected. The fixation, embedding (with Paraffin), sectioning and hematoxylin and eosin (H&E) staining of tumor samples were performed by the Histopathology Facility at Fox Chase Cancer Center.

**Statistical analysis**

Results are presented as the mean ± standard deviation (SD). Difference comparisons were performed with Prism software using the Student’s two-tailed t test. Statistically significant differences were determined by P value < 0.05.

**Correlation analysis**

Gene expression correlation analysis was performed using the GEPIA web server (http://gepia.cancer-pku.cn/) on colon adenocarcinoma TCGA data. Pearson correlation coefficient was calculated. The Kaplan-Meier plot was generated using UCSC Xena based on TCGA colon and rectal cancer (https://xena.ucsc.edu/) or using the GEPIA tool based on TCGA pancreatic adenocarcinoma cancer.

**Author contributions**
S. Zhao participated in the conception, design, data acquisition and writing of the manuscript. L.Z. participated in the design and performance of in vivo study. D.T.D. participated in flow cytometry analysis. A.L. participated in helpful discussions. S. Zhang participated in discussion, provided technical advice and assisted with editing the manuscript. W.S.E-D. supervised this work and participated in the conception, design, analysis, writing and revision of the manuscript. W.S.E-D. provided oversight of the research as well as resources.

Competing interests
The authors declare no competing interests.

Acknowledgements
We thank the El-Deiry lab members for all the helpful discussions. This work was presented in part as it progressed each year at the annual American Association for Cancer Research (AACR) meetings in 2016, 2017, 2018, 2019, and 2020. W.S.E-D. is an American Cancer Society (ACS) Research Professor and was supported by the William Wikoff Smith endowed professorship in cancer research at Fox Chase Cancer Center and by the Mencoff Family University Professorship in Medical Science at Brown University.
Reference


Figure legends

**Figure 1.** CDK1 contributes to HSP90-mediated HIF1α stabilization. (A) Inhibition of CDK1 decreases the level of HIF1α in RCC4 cells independently of VHL. Cells were treated with Ro-3306 (5 µM) or MG132 (1 µM) or both as indicated for 6 hours under normoxia. (B) CDK1 inhibition (for 6 hours under hypoxia; 0.5% O2) impairs the interaction between HIF1α and HSP90. HCT116 cells were treated with MG132 and cultured in hypoxia for 6 hours with or without Ro-3306. Cells were fixed and lysed for co-immunoprecipitation analysis. (C) CDK1 partially reversed heat shock-induced HIF1α expression. HCT116 cells were treated at 40°C with the indicated inhibitors for 6 hours.

**Figure 2.** Dual inhibition of CDK1 and HSP90 robustly reduces the level of HIF1α. (A) HCT116, (C) HCT116 p53-/- cells or (D) other colorectal cell lines were treated with control or CDK1 siRNA for 48 hours, followed by treatment with DMSO or geldanamycin under hypoxia (0.5% O2) for 6 hours. (B) Cells were treated with Ro-3306, geldanamycin, or the combination of both for 6 hours under hypoxia.

**Figure 3.** Ro-3306 and geldanamycin synergistically inhibit HCT116 cell viability through induction of apoptosis. (A) In normoxia or (B) hypoxia (0.5% O2), cells were treated with Ro-3306 and geldanamycin at the indicated concentrations for (A) 48 or (B) 72 hours. (C) Sub-G1 analysis by propidium iodide staining and flow cytometry of cells treated with Ro-3306 (10 µM) and geldanamycin (1 µM) under normoxia for 48 hours or under hypoxia for 72h. (D) Western blot of PARP cleavage in cells treated with Ro-3306 or geldanamycin or both. (E) CellTiter-Glo analysis of cell viability in HCT116 Bax-/- cells treated at indicated concentrations under normoxia for 48 hours. ** p<0.01; *** p<0.005; **** p<0.001.

**Figure 4.** Combination CDK1 and HSP90 inhibitor treatment inhibits colony formation and migration in HCT116 cells. (A) In normoxia or (B) In hypoxia (0.5% O2), HCT116 cells were treated with the indicated combination treatments for 72 hours. Drug-containing media was replaced with regular culture media, and cells were allowed to grow and form colonies for 1 week. (C) Scratch assay and (D) quantification for HCT116 cells under normoxia for 48 hours. Gap ratio
refers to the ratio of gap width at 48 hours versus at 0 hours. Cells were treated with Z-VAD caspase inhibitor to prevent cell death. (R: Ro-3306; G: geldanamycin.) n=3. ** p<0.01; *** p<0.005; **** p<0.001.

**Figure 5.** Dual inhibition of CDK4/6 and HSP90 reduces HIF1α in colorectal cancer cells and synergistically inhibits cell viability in HCT116. (A) HCT116 cells were treated with the indicated inhibitors (ganetespib at 0.05 µM and palbociclib at 10 µM) for 6 hours under hypoxia (0.5% O2). (B) SW480 cells were treated with the indicated inhibitors (ganetespib at 0.05 µM, onalespib at 0.05 µM, and palbociclib at 10 µM) for 6 hours under hypoxia (0.5% O2). (C, D) CDK4 inhibitor palbociclib and HSP90 inhibitor ganetespib or onalespib synergistically inhibit the viability of HCT116 cells at 72 hours in normoxia and hypoxia (0.5% O2). (E) Sub-G1 analysis by propidium iodide staining and flow cytometry for HCT116 cells treated with the indicated drug combinations (ganetespib at 0.04 µM; palbociclib at 10 µM) for 48 hours. (F) Scratch assay in HT29 cells under CoCl2 treatment (50µM) to mimic hypoxia for 72 hours. (P: palbociclib; G: ganetespib.) * p< 0.05; ** p<0.01; *** p<0.005.

**Figure 6.** Combination treatment with palbociclib and ganetespib inhibits tumor growth in vivo. (A) Tumors excised from HT29 xenografts in nude mice. (B) Tumor weight quantification of excised tumors. (C) Relative tumor volume measured over time. Tumor volumes were normalized to those at the beginning of treatment. (D) Body weight of mice in different treatment groups. (E) Combination treatment inhibits microvessel formation in tumors in vivo. # control vs. combination: p<0.05; * ganetespib vs. combination: p<0.05.

**Figure 7.** Rb-deficiency does not affect the combinatorial inhibition of HIF1α expression and cell viability. (A, B) Combination treatment with abemaciclib and TAS116 synergistically inhibits cell viability in Saos2 osteosarcoma cells at 72 hours under (A) normoxia and (B) hypoxia (0.5% O2). (C) SW480 cells were incubated with Rb-targeting siRNA for 48 hours and subsequently treated with 1 µM abemaciclib and/or 0.5 µM TAS116 for 6 hours in hypoxia (0.5% O2). (D) Knockdown of Rb does not affect HIF1α inhibition by combination drug treatment with TAS116 and abemaciclib in MCF7 breast cancer cells. (E, F) SW480 cells were treated with (E) mock or (F)
Rb-targeting siRNA for 48 hours and subsequently treated with indicated combinations under normoxia (upper) or 0.5% O₂ hypoxia (lower).

**Figure 8.** Correlation between the overexpression of HIF1α target genes *VEGFA* and *SLC2A1* and poor disease-free interval. The analysis was performed with the UCSC Xena tool on TCGA colon and rectal cancer samples. (A) Correlation between *VEGFA* expression and disease-free interval. P value=0.0001. (B) Correlation between *SLC2A1* expression and disease-free interval. P value=0.034.
### Figure 1

#### A

<table>
<thead>
<tr>
<th></th>
<th>RCC4</th>
<th>RCC4+VHL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ro-3306</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>MG132</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Western Blot:**
- **HIF1α**
- **VHL**
- **β-Actin**

#### B

**IP:**
- HA-HIF1α
- HCT116

**Transfected:**
- HA-HIF1α

**Input:**
- HSP90

#### C

<table>
<thead>
<tr>
<th></th>
<th>37°C</th>
<th>40°C</th>
</tr>
</thead>
<tbody>
<tr>
<td>no treatment</td>
<td>no treatment</td>
<td>Geldanamycin</td>
</tr>
</tbody>
</table>

**Western Blot:**
- **HIF1α**
- **β-Actin**
Figure 2

A. Western blot analysis of HIF1α, CDK1, and β-Actin in SW480 cells treated with DMSO, Ro-3306, and Geldanamycin, with and without siCDK1.

B. Western blot analysis of HIF1α and β-Actin in RKO cells treated with DMSO, Ro-3306, and Geldanamycin, with and without siCDK1.

C. Western blot analysis of HIF1α, CDK1, and β-Actin in SW480 cells treated with DMSO, Ro-3306, and Geldanamycin, with and without siCDK1.

D. Western blot analysis of HIF1α, CDK1, and β-Actin in HT29 and DLD-1 cells treated with siCDK1 and Geldanamycin.

E. Western blot analysis of HIF1α, CDK1, and β-Actin in SW480 and RKO cells treated with siCDK1 and Geldanamycin.
Figure 3
Figure 4
Figure 5
Figure 6

A) Control, Palbociclib, Ganetespib, and Palbociclib+Ganetespib tumor samples over time.

B) Tumor weight (mg) comparison among Control, Palbociclib, Ganetespib, and Palbociclib+Ganetespib groups.

C) Relative tumor volume over days for Control, Palbociclib, Ganetespib, and Palbociclib+Ganetespib.

D) Body weight (g) over days for Control, Palbociclib, Ganetespib, and Palbociclib+Ganetespib.

E) Histological images of Control, Ganetespib, Palbociclib, and Palbociclib+Ganetespib.
**Figure 7**

Panel A:
- **TAS116 (μM)**
- "abemaciclib (μM)" 0 0.25 0.5 1 2
- Images of Western blots showing effects of TAS116 and abemaciclib on HIF1α, β-Actin, and Rb levels.

Panel B:
- **TAS116 (μM)**
- "abemaciclib (μM)" 0 0.25 0.5 1 2
- Images of Western blots showing effects of TAS116 and abemaciclib on HIF1α, β-Actin, and Rb levels.

Panel C:
- **TAS116 (μM)**
- "abemaciclib (μM)" 0 0.25 0.5 1 2
- Images of Western blots showing effects of TAS116 and abemaciclib on HIF1α, β-Actin, and Rb levels.

Panel D:
- **TAS116 (μM)**
- "abemaciclib (μM)" 0 0.25 0.5 1 2
- Images of Western blots showing effects of TAS116 and abemaciclib on HIF1α, β-Actin, and Rb levels.

Panel E:
- **TAS116 (μM)**
- "abemaciclib (μM)" 0 0.25 0.5 1 2
- Images of Western blots showing effects of TAS116 and abemaciclib on HIF1α, β-Actin, and Rb levels.

Panel F:
- **TAS116 (μM)**
- "abemaciclib (μM)" 0 0.25 0.5 1 2
- Images of Western blots showing effects of TAS116 and abemaciclib on HIF1α, β-Actin, and Rb levels.
Figure 8
Supplementary Figure Legends

Supplementary figure 1. Dual inhibition of CDK4 and HSP90 decreases HIF1α level and synergistically inhibits cell viability in SW480 cells. (A) SW480 cells were treated with DMSO or ganetespib (1 µM) after 48 hours of knockdown of CDK4. (B, C) SW480 cells were treated with palbociclib and onalespib at the indicated doses for 72 hours in (B) normoxia and (C) hypoxia (0.5% O2).

Supplementary figure 2. Combination treatment with the HSP90 inhibitor XL-888 and CDK4/6 inhibitor palbociclib inhibits HIF1α and cell viability in colorectal cancer. (A) HCT116 and (B) HT29 colon cancer cells were treated with indicated inhibitors (XL-888 at 0.05 µM, onalespib at 0.05 µM, and palbociclib at 10 µM) for 6 hours under hypoxia (0.5% O2). (C, D) In HCT116 and (E, F) SW480 colon cancer cells, XL-888 and palbociclib synergistically inhibit cell viability under (C, E) normoxia and (D, F) hypoxia (0.5% O2).

Supplementary figure 3. The combinatorial effect of CDK4/6 inhibitors with HSP90 inhibitors applies to alternative inhibitors in SW480 cells. (A) SW480 cells were treated with the indicated inhibitors (TAS-116 at 0.5 µM and palbociclib at 10 µM) for 6 hours under hypoxia (0.5% O2). (B, C) CDK4 inhibitor palbociclib and HSP90 inhibitor TAS-116 synergistically inhibit the viability of SW480 cells in (B) normoxia and (C) hypoxia (0.5% O2). (D) SW480 cells were treated with indicated inhibitors (TAS-116 at 0.5 µM and abemaciclib at 10 µM) for 6 hours under hypoxia (0.5% O2). (E, F) CDK4 inhibitor abemaciclib and HSP90 inhibitor TAS-116 synergistically inhibit the viability of SW480 cells in (B) normoxia and (C) hypoxia (0.5% O2).

Supplementary figure 4. Dose response curve of ganetespib in colorectal cancer cell lines. (A) In normoxia or (B) in hypoxia (0.5% O2), cells were treated with increasing doses of ganetespib for 72 hours. Null: HCT116 p53−/− colorectal cancer cells.

Supplementary figure 5. Combinatorial treatment by CDK4/6 inhibitor palbociclib and HSP90 inhibitor ganetespib increased caspase 3 cleavage and inhibited VEGF expression in xenograft tumors. (A) IHC staining of cleaved caspase 3. (B) IHC staining of VEGF.
**Supplementary figure 6.** Dual inhibition of CDK4 and HSP90 inhibits HIF1α and cell viability in multiple cancer types. (A) ASPC1 and (B) HPAFII pancreatic cancer cells as well as (C) SKBR3 and (D) MDA-MB-361 breast cancer cells were treated with the indicated inhibitors (TAS-116 at 0.5 µM, palbociclib at 10 µM and abemaciclib at 1µM) for 6 hours under hypoxia (0.5% O₂). (E) In normoxia and (F) hypoxia (0.5% O₂), CDK4 inhibitor palbociclib and HSP90 inhibitor TAS-116 inhibit the viability of SKBR3 cells.

**Supplementary figure 7.** Dual inhibition of CDK4/6 and HSP90 robustly decreases the levels of HIF1α in multiple cancer cell types. (A) T98G cells were treated with palbociclib or ganetespib or the combination of both in hypoxia (0.5% O₂) for 6 hours. (B) PC3 cells were treated with ganetespib for 6 hours under hypoxia (0.5% O₂) after 48 hours of knockdown of CDK4.

**Supplementary figure 8.** Combination of CDK1 inhibitor Ro-3306 or CDK4/6 inhibitor palbociclib and HSP90 inhibitor ganetespib does not induce cell death in WI38 normal cells in normoxia.

**Supplementary figure 9.** Dual inhibition of CDK4/6 and HSP90 slightly inhibits HIF2α in HCT116 cells. Cells were treated with the indicated inhibitors (ganetespib at 0.05 µM, onalespib at 0.05 µM, palbociclib and abemaciclib at 10 µM) for 6 hours under hypoxia (0.5% O₂).

**Supplementary figure 10.** Overexpression of HIF1α<sup>668E</sup> partially rescued the cell viability inhibition by combination of CDK4/6 and HSP90 inhibitor treatment under hypoxia. Cells were transfected with pcDNA3 plasmid carrying (A) HA tag or (B) HA-HIF1α<sup>668E</sup> for 48 hours, and subsequently treated with the indicated drug combinations for 72 hours under hypoxia (0.5% O₂). (C) HIF1α overexpression by HA-HIF1α<sup>668E</sup> at 48 hours post transfection or 48 hours transfection plus 6 hours 0.5% O₂ hypoxia treatment.

**Supplementary figure 11.** Pearson correlation analysis between HIF1α and E2F target genes in colon adenocarcinoma. The analysis is performed using the GEPIA online tool based on TCGA colon adenocarcinoma data.
Supplementary figure 12. Analysis of TCGA data in pancreatic adenocarcinoma (PAAD). (A) Overexpression of HIF1α target genes SLC2A1 and PPIA is correlated with poor overall survival and disease-free survival in PAAD patients. (B) Correlations between HIF1α target genes (SLC2A1 and PPIA) and E2F target genes (RRM2, CCNA2 and CDC6) based on TCGA PAAD data.
Supplementary figure 1

A

<table>
<thead>
<tr>
<th></th>
<th>mock</th>
<th>siCDK4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ganetespib</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>HIF1α</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDK4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-Actin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

C

Palbociclib    0   0.05   0.1   0.2   0.4

Onalgespib

0   2.5   5   10   5

Hypoxia

Normoxia

** ****

P-G- P-G+ P-G+ P+G+

Mock siCDK4

Ganetespib +

HIF1α

β-Actin

Ro3306

Geldanamycin

- - + +

+ + + +

Ganetespib

Palbociclib

Ro3306

Geldanamycin

- - + +

+ + + +

Hypoxia

Normoxia

18.8% 15.0% 31.3% 47.1%

11.8% 12.4% 22.7% 32.1%

Sub-G1 (%)

Data 1

Data 2

R+G- R+G+ R-G- R-G +

HCT116 N 48h

****

****

****

****

****

P-G- P+G- P-G+ P+G+

Ro3306

Geldanamycin

- - + +

+ + + +

Ro3306

Geldanamycin

- - + +

+ + + +

Ro3306

Geldanamycin

- - + +

+ + + +

Ro3306

Geldanamycin

- - + +

+ + + +

HT29 PD GT migration CoCl2

Gap ratio

***

**

*

***

**

*

***

**

*

***

**

*
Supplementary figure 4
Dose TAS Dose PD Effect CI
0.25 2.5 0.832 1.31727
0.25 5.0 0.699 1.07723
0.25 10.0 0.513 0.94918
0.5 2.5 0.595 0.87099
0.5 5.0 0.497 0.82126
0.5 10.0 0.337 0.70705
1.0 2.5 0.468 1.05769
1.0 5.0 0.376 0.92296
1.0 10.0 0.218 0.65901
2.0 2.5 0.336 1.33281
2.0 5.0 0.284 1.20584
2.0 10.0 0.166 0.83891
Combination Index Plot

Dose TAS Dose PD DRI TAS DRI PD
0.25 2.5 0.33083 4.45158 1.32333 1.78063
0.25 5.0 0.56074 7.91903 2.24296 1.58381
0.25 10.0 0.97266 14.4476 3.89064 1.44476
0.5 2.5 0.77144 11.2179 1.54289 4.48717
0.5 5.0 1.01702 15.1684 2.03404 3.03369
0.5 10.0 1.61605 25.1478 3.23209 2.51478
0.5 2.5 1.10276 16.5697 1.10276 6.62789
0.5 5.0 1.43541 22.0954 1.43541 4.41909
0.5 10.0 2.45587 39.7109 2.45587 3.97109
Combination Index Plot

Dose TAS Dose PD Effect CI
0.25 2.5 0.948 2.19459
0.25 5.0 0.657 1.00375
0.25 10.0 0.263 1.06911
0.5 2.5 0.584 0.84992
0.5 5.0 0.324 0.76031
0.5 10.0 0.058 0.74734
1.0 2.5 0.395 0.88982
1.0 5.0 0.186 0.73569
1.0 10.0 0.057 0.80028
2.0 2.5 0.297 1.15460
2.0 5.0 0.124 0.81850
2.0 10.0 0.063 0.94464
Combination Index Plot
### Table: Ganetespib (μM) and Palbociclib (μM) Treatments

<table>
<thead>
<tr>
<th>Ganetespib (μM)</th>
<th>0</th>
<th>2.5</th>
<th>5</th>
<th>2.5</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>normoxia 72h</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.02</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.04</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Supplementary figure 8**
**Supplementary figure 9**

**A**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>HIF2α</th>
<th>β-Actin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onalespib</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Palbociclib</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Ganetespib</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

**B**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>HIF2α</th>
<th>β-Actin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onalespib</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Palbociclib</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Abemaciclib</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

*Note: The images show immunoblotting results for HIF2α and β-Actin under different treatments.*
### Table A

<table>
<thead>
<tr>
<th>Dose Abemacibl</th>
<th>Dose TAS116</th>
<th>Effect</th>
<th>CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.25</td>
<td>0.25</td>
<td>0.60081</td>
<td>0.81050</td>
</tr>
<tr>
<td>0.25</td>
<td>0.5</td>
<td>0.53226</td>
<td>0.72617</td>
</tr>
<tr>
<td>0.25</td>
<td>1.0</td>
<td>0.36411</td>
<td>0.64897</td>
</tr>
<tr>
<td>0.25</td>
<td>2.0</td>
<td>0.18427</td>
<td>0.91638</td>
</tr>
<tr>
<td>0.25</td>
<td>4.0</td>
<td>0.11452</td>
<td>1.36838</td>
</tr>
<tr>
<td>0.5</td>
<td>0.25</td>
<td>0.67472</td>
<td>2.29140</td>
</tr>
<tr>
<td>0.5</td>
<td>0.5</td>
<td>0.52823</td>
<td>1.14278</td>
</tr>
<tr>
<td>0.5</td>
<td>1.0</td>
<td>0.20605</td>
<td>0.50392</td>
</tr>
<tr>
<td>0.5</td>
<td>2.0</td>
<td>0.1121</td>
<td>0.70726</td>
</tr>
<tr>
<td>0.5</td>
<td>4.0</td>
<td>0.14395</td>
<td>1.49483</td>
</tr>
<tr>
<td>1.0</td>
<td>0.25</td>
<td>0.39919</td>
<td>0.93120</td>
</tr>
<tr>
<td>1.0</td>
<td>1.0</td>
<td>0.1125</td>
<td>0.40914</td>
</tr>
<tr>
<td>1.0</td>
<td>2.0</td>
<td>0.08548</td>
<td>0.67017</td>
</tr>
<tr>
<td>1.0</td>
<td>4.0</td>
<td>0.06492</td>
<td>1.18858</td>
</tr>
<tr>
<td>2.0</td>
<td>0.25</td>
<td>0.19449</td>
<td>1.76060</td>
</tr>
<tr>
<td>2.0</td>
<td>0.5</td>
<td>0.1125</td>
<td>0.40914</td>
</tr>
<tr>
<td>2.0</td>
<td>1.0</td>
<td>0.08548</td>
<td>0.67017</td>
</tr>
<tr>
<td>2.0</td>
<td>4.0</td>
<td>0.06492</td>
<td>1.18858</td>
</tr>
</tbody>
</table>

### Table B

<table>
<thead>
<tr>
<th>Dose Abemacibl</th>
<th>Dose TAS116</th>
<th>Effect</th>
<th>CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.25</td>
<td>0.25</td>
<td>0.8651</td>
<td>1.23137</td>
</tr>
<tr>
<td>0.25</td>
<td>0.5</td>
<td>0.6601</td>
<td>1.10031</td>
</tr>
<tr>
<td>0.25</td>
<td>1.0</td>
<td>0.34098</td>
<td>0.73422</td>
</tr>
<tr>
<td>0.25</td>
<td>2.0</td>
<td>0.1003</td>
<td>0.50315</td>
</tr>
<tr>
<td>0.25</td>
<td>4.0</td>
<td>0.21786</td>
<td>1.56926</td>
</tr>
<tr>
<td>0.5</td>
<td>0.25</td>
<td>0.56764</td>
<td>0.68741</td>
</tr>
<tr>
<td>0.5</td>
<td>0.5</td>
<td>0.5131</td>
<td>0.86956</td>
</tr>
<tr>
<td>0.5</td>
<td>1.0</td>
<td>0.22546</td>
<td>0.66276</td>
</tr>
<tr>
<td>0.5</td>
<td>2.0</td>
<td>0.16059</td>
<td>0.62078</td>
</tr>
<tr>
<td>0.5</td>
<td>4.0</td>
<td>0.1535</td>
<td>1.30184</td>
</tr>
<tr>
<td>1.0</td>
<td>0.25</td>
<td>0.5713</td>
<td>1.09282</td>
</tr>
<tr>
<td>1.0</td>
<td>0.5</td>
<td>0.37087</td>
<td>0.99393</td>
</tr>
<tr>
<td>1.0</td>
<td>1.0</td>
<td>0.10589</td>
<td>0.67811</td>
</tr>
<tr>
<td>1.0</td>
<td>2.0</td>
<td>0.07279</td>
<td>0.85177</td>
</tr>
<tr>
<td>1.0</td>
<td>4.0</td>
<td>0.07353</td>
<td>1.04801</td>
</tr>
<tr>
<td>2.0</td>
<td>0.25</td>
<td>0.19449</td>
<td>1.21380</td>
</tr>
<tr>
<td>2.0</td>
<td>0.5</td>
<td>0.1981</td>
<td>1.30167</td>
</tr>
<tr>
<td>2.0</td>
<td>1.0</td>
<td>0.1203</td>
<td>1.20264</td>
</tr>
<tr>
<td>2.0</td>
<td>2.0</td>
<td>0.08474</td>
<td>1.24520</td>
</tr>
<tr>
<td>2.0</td>
<td>4.0</td>
<td>0.1203</td>
<td>1.91443</td>
</tr>
</tbody>
</table>

### Supplementary figure 10

- **A**: Abemaciclib and TAS116 treatment for 48h under hypoxia conditions. The figure shows the co-localization of Abemaciclib and TAS116 with HA and HA-HIF1αS668E.
- **B**: Similar to A, but without hypoxia conditions. The figure shows the co-localization of Abemaciclib and TAS116 with HA and HA-HIF1αS668E.
- **C**: Western blot analysis showing the effect of Abemaciclib and TAS116 on HIF1α and Ran levels after 48h and 48h+6h hypoxia conditions.
Supplementary figure 11